Search

US-20260124133-A1 - AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION

US20260124133A1US 20260124133 A1US20260124133 A1US 20260124133A1US-20260124133-A1

Abstract

A method of modulating topical pH of a subject is provided. The methods include administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. The methods include administering the preparation comprising ammonia oxidizing microorganisms topically to skin of the subject. Related preparations and kits are also provided.

Inventors

  • Carson Alexis Goddard

Assignees

  • AOBIOME LLC

Dates

Publication Date
20260507
Application Date
20251230

Claims (20)

  1. 1 . A method of modulating topical pH of a subject, comprising: administering to the subject an effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM), thereby modulating topical pH of the subject.
  2. 2 . The method of claim 1 , wherein administration comprises topical application of the preparation to the skin of the subject.
  3. 3 . The method of claim 1 , comprising administering the preparation in an amount sufficient to control topical pH of the subject.
  4. 4 . The method of claim 3 , comprising administering the preparation in an amount sufficient to control topical pH of the subject to be between about 5 and 7.5.
  5. 5 . The method of claim 1 , comprising administering the preparation in an amount sufficient to decrease topical pH of the subject.
  6. 6 . The method of any of claims 3-5 , wherein administration provides for controlling, decreasing, or increasing topical pH of the subject by local administration.
  7. 7 . The method of any of claims 3-5 , wherein administration provides for controlling, decreasing, or increasing topical pH of the subject by systemic administration.
  8. 8 . The method of any of claims 1 and 2 , comprising administering the preparation in an amount sufficient to improve barrier function associated with skin of the subject.
  9. 9 . The method of claim 9 , comprising administering the preparation in an amount sufficient to alter desquamation of the stratum corneum and/or control enzymatic degradation of kallikrein 5 and/or kallikrein 7.
  10. 10 . The method of any of claims 1 and 2 , comprising administering the preparation in an amount sufficient to prevent induction of an inflammatory response.
  11. 11 . The method of claim 10 , comprising administering the preparation in an amount sufficient to activate IL-1 beta and/or control enzymatic degradation of kallikrein 7.
  12. 12 . The method of any of claims 1 and 2 , comprising administering an effective amount of the preparation to change or alter a level of nitrite or NO in the subject.
  13. 13 . The method of any of claims 1 and 2 , comprising administering an effective amount of the preparation to modulate a microbiome associated with the skin of the subject.
  14. 14 . The method of any of claims 1 and 2 , wherein the preparation is formulated as a liquid, droplet, powder, solid, cream, lotion, gel, stick, aerosol, spray, mist, salve, wipe, or bandage.
  15. 15 . The method of any of claims 1 and 2 , wherein the effective amount is a therapeutically effective dose of AOM, e.g., a therapeutically effective dose of about or greater than about 1×10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 CFU of AOM.
  16. 16 . The method of any of claims 1 and 2 , wherein the buffer solution, e.g., aqueous buffer solution, comprises disodium phosphate and magnesium chloride, for example, 50 mM Na 2 HPO 4 and 2 mM MgCl 2 in water.
  17. 17 . The method of claim 16 , wherein the buffer solution e.g., aqueous buffer solution, consists essentially of disodium phosphate and magnesium chloride, for example, 50 mM Na 2 HPO 4 and 2 mM MgCl 2 in water.
  18. 18 . The method of any of claims 1 and 2 , wherein the AOB comprise Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio , and combinations thereof.
  19. 19 . The method of claim 16 , wherein the AOB is Nitrosomonas eutropha ( N. eutropha ).
  20. 20 . The method of claim 17 , wherein the AOB is N. eutropha D23, having ATCC accession number PTA-121157.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. patent application Ser. No. 19/175,417 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Apr. 10, 2025, which is a continuation of U.S. patent application Ser. No. 18/910,333 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Oct. 9, 2024, which is a continuation of U.S. patent application Ser. No. 18/599,169 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Mar. 7, 2024, which is a continuation of U.S. patent application Ser. No. 18/240,511 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Aug. 31, 2023, which is a continuation of U.S. patent application Ser. No. 18/163,581 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Feb. 2, 2023, which is a continuation of U.S. patent application Ser. No. 17/879,349 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Aug. 2, 2022, which is a continuation of U.S. patent application Ser. No. 17/436,386 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Sep. 3, 2021, which is a U.S. national phase application, and claims the benefit of priority under 35 U.S.C. § 371, of International (PCT) Patent Application Serial No. PCT/US2020/021482 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed on Mar. 6, 2020, which claims priority under 35 U.S.C. § 119 (e) to U.S. Provisional Application No. 62/814,608 titled “AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION,” filed Mar. 6, 2019, the entire disclosure of each of which is hereby incorporated herein by reference in its entirety for all purposes. FIELD OF THE TECHNOLOGY Aspects relate generally to the microbiome and, more specifically, to the restoration of ammonia oxidizing microorganisms in relation to the microbiome. BACKGROUND Bacteria and other microorganisms are ubiquitous in the environment. The discovery of pathogenic bacteria and the germ theory of disease have had a tremendous effect on health and disease states. Microorganisms are a normal part of the environment of all living things and may be beneficial. In the gut, for example, bacteria are not pathogenic under normal conditions, and in fact improve health by rendering the normal intestinal contents less hospitable for disease causing organisms. SUMMARY In accordance with one or more aspects, a method of modulating topical pH of a subject is disclosed. The method may comprise administering to the subject an effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM), thereby modulating pH of the subject. In some aspects, administration may comprise topical application to skin of the subject. The effective amount of the preparation may be administered to a face of the subject. The effective amount of the preparation may be administered to a body of the subject. The preparation may be administered in response to an insult to skin of the subject. An amount and/or a frequency of administration may be sufficient to control topical pH of the subject. An amount and/or a frequency of administration may be sufficient to decrease topical pH of the subject. An amount and/or a frequency of administration may be sufficient to increase topical pH of the subject. An amount and/or a frequency of administration may be sufficient to control topical pH of the subject to be between about 5 and 7.5 Administration may provide for controlling, decreasing, or increasing topical pH of the subject by local administration. Administration may provide for controlling, decreasing, or increasing pH of the subject by systemic administration. An amount and/or a frequency of administration may be sufficient to improve barrier function associated with skin of the subject. An amount and/or a frequency of administration may be sufficient to alter desquamation of the stratum corneum and/or control enzymatic degradation of kallikrein 5 and/or kallikrein 7. An amount and/or a frequency of administration may be sufficient to prevent induction of an inflammatory response. An amount and/or a frequency of administration may be sufficient to activate IL-1 beta and/or control enzymatic degradation of kallikrein 7. In some aspects, the preparation may be administered subsequent to washing the skin of the subject. A target percentage of administered AOM may be transferred to the skin of the subject. The preparation may be applied to target skin of the subject associated with a desired local effect. The preparation may be applied to one or more of the forehead, eye region, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, or buttocks of the subject. Administering an effective amount of the preparation may change or alter a level of nitrite or NO in the subject. Administering an effective amount of the preparation may modulate a microbiome associated with the skin of the subject. The method may further comprise modulating a microbiome asso